Skip to content

Lincomycin Hydrochloride

FDA-approved product (capsule, oral), marketed as Lincocin, Lincomycin Hydrochloride.

Registered studies
50+
Lab records
9
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Lincomycin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection
  • Multiple sclerosis
  • Pseudomembranous enterocolitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Lincosamides
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01FF02

Repurposing investigation

Lincomycin Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli4.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae8.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis4.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 2 of 3 lab records
  • E. coli: measured active in 0 of 1 lab record
  • K. pneumoniae: measured active in 0 of 1 lab record
  • M. tuberculosis: measured active in 0 of 4 lab records
Show the 9 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lincomycin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

    NCT03511118 · start 2018-10-04

    Registered record
    Registry ID
    NCT03511118
    Conditions
    Lactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    Interventions
    Tranexamic acid (TXA); labetalol; metformin; nifedipine; clindamycin; oxycodone; azithromycin; escitalopram; sertraline; ondansetron; Ciprofloxacin; Doxycycline; Levofloxacin; Methylphenidate; Sumatriptan; Citalopram; Cyclobenzaprine; Furosemide; Gabapentin; Hydrochlorothiazide; Hydroxyurea; Rosuvastatin; Topiramate; Trazodone; Valganciclovir; Venlafaxine; Verapamil; Remdesivir; Anakinra; Tocilizumab; Fluvoxamine; Amoxicillin; Bupropion; Duloxetine; Hydrocodone; Levetiracetam; Paroxetine; Buprenorphine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-10-04
    Completion
    2028-07-31
    Enrolment
    1,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    InterventionTranexamic acid (TXA); labetalol; metformin; nifedipine +34 more
    PhaseNot recorded
    Registry statusRecruiting
  • A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris

    NCT03615768 · start 2018-08-14

    Registered record
    Registry ID
    NCT03615768
    Conditions
    Acne Vulgaris
    Interventions
    Adapalene-Clindamycin Combination Gel; Adapalene Gel; Clindamycin Gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-08-14
    Completion
    2020-04-07
    Enrolment
    1,617

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionAdapalene-Clindamycin Combination Gel; Adapalene Gel; Clindamycin Gel
    PhasePhase 3
    Registry statusCompleted
  • Application of Intra-operative Prophylactic Antibiotics/Antiseptics in Chinese Breast Reconstruction Patients

    NCT03742908 · start 2018-06-16

    Registered record
    Registry ID
    NCT03742908
    Conditions
    Breast Neoplasms
    Interventions
    Cefazolin/clindamycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-06-16
    Completion
    2021-10-31
    Enrolment
    291

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms
    InterventionCefazolin/clindamycin
    PhaseNot applicable
    Registry statusUnknown
  • Antibiotics During Intrauterine Balloon Tamponade Placement

    NCT03478163 · start 2018-03-08

    Registered record
    Registry ID
    NCT03478163
    Conditions
    Obstetric Complication; Postpartum Hemorrhage; Postpartum Endometritis
    Interventions
    CeFAZolin 1000 MG; Clindamycin 900 MG in 6 ML Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2018-03-08
    Completion
    2021-05-03
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstetric Complication; Postpartum Hemorrhage; Postpartum Endometritis
    InterventionCeFAZolin 1000 MG; Clindamycin 900 MG in 6 ML Injection
    PhasePhase 4
    Registry statusTerminated
  • Topical Treatment and Prevalence of P. Acnes

    NCT03257202 · start 2017-09-11

    Registered record
    Registry ID
    NCT03257202
    Conditions
    Surgical Site Infection
    Interventions
    Clindamycin 1% Gel; Benzoyl peroxide 5% gel; BenzaClin 5%-1% Topical Gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-09-11
    Completion
    2018-01-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurgical Site Infection
    InterventionClindamycin 1% Gel; Benzoyl peroxide 5% gel; BenzaClin 5%-1% Topical Gel
    PhasePhase 2
    Registry statusCompleted
  • Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS)

    NCT03261830 · start 2017-08-18

    Registered record
    Registry ID
    NCT03261830
    Conditions
    Supracondylar Humerus Fracture; Post Operative Wound Infection
    Interventions
    Cefazolin; Clindamycin; Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-08-18
    Completion
    2023-03-10
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSupracondylar Humerus Fracture; Post Operative Wound Infection
    InterventionCefazolin; Clindamycin; Saline
    PhasePhase 4
    Registry statusCompleted
  • Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

    NCT02814916 · start 2017-03-30

    Registered record
    Registry ID
    NCT02814916
    Conditions
    Methicillin-Resistant Staphylococcus Aureus; Bacterial Infections; Staphylococcal Skin Infections
    Interventions
    Dalbavancin; Vancomycin; Oxacillin; Flucloxacillin; Cefadroxil; Clindamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-03-30
    Completion
    2024-01-01
    Enrolment
    199

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethicillin-Resistant Staphylococcus Aureus; Bacterial Infections; Staphylococcal Skin Infections
    InterventionDalbavancin; Vancomycin; Oxacillin; Flucloxacillin +2 more
    PhasePhase 3
    Registry statusCompleted
  • Antibiotics and Tissue Expanders in Breast Reconstruction

    NCT01899690 · start 2016-06

    Registered record
    Registry ID
    NCT01899690
    Conditions
    Complications; Breast Prosthesis, Infection or Inflammation
    Interventions
    antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2016-06
    Completion
    2017-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplications; Breast Prosthesis, Infection or Inflammation
    Interventionantibiotic
    PhasePhase 4
    Registry statusWithdrawn
  • Aspiration Treatment of Perianal Abscess

    NCT02585141 · start 2015-10

    Registered record
    Registry ID
    NCT02585141
    Conditions
    Anal Fistulas
    Interventions
    MEDIPLAST® (aspiration); incision; Clindamycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-10
    Completion
    2020-06
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnal Fistulas
    InterventionMEDIPLAST® (aspiration); incision; Clindamycin
    PhaseNot applicable
    Registry statusCompleted
  • To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.

    NCT02465632 · start 2015-04

    Registered record
    Registry ID
    NCT02465632
    Conditions
    Acne Vulgaris
    Interventions
    Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel; BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-04
    Completion
    2015-12
    Enrolment
    1,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionClindamycin 1%/Benzoyl Peroxide 5% Topical Gel; BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%; Placebo
    PhasePhase 3
    Registry statusCompleted
  • Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne

    NCT02593383 · start 2015-03-01

    Registered record
    Registry ID
    NCT02593383
    Conditions
    Acne
    Interventions
    Adapalene + Clindamycin Hydrochloride; Adapalene + Clindamycin Hydrochloride; Adapalene + Clindamycin Hydrochloride; Adapalene + Clindamycin Hydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-03-01
    Completion
    2017-07-31
    Enrolment
    245

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne
    InterventionAdapalene + Clindamycin Hydrochloride; Adapalene + Clindamycin Hydrochloride; Adapalene + Clindamycin Hydrochloride; Adapalene + Clindamycin Hydrochloride +1 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted
  • A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne Vulgaris

    NCT02595034 · start 2015-01

    Registered record
    Registry ID
    NCT02595034
    Conditions
    Acne Vulgaris
    Interventions
    Clindamycin and Benzoyl Peroxide Gel 1%5%; BenzaClin® Topical Gel; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-01
    Completion
    2015-11
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionClindamycin and Benzoyl Peroxide Gel 1%5%; BenzaClin® Topical Gel; Placebo
    PhasePhase 1
    Registry statusCompleted
  • Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy

    NCT02579161 · start 2014-09

    Registered record
    Registry ID
    NCT02579161
    Conditions
    Kidney Stones
    Interventions
    cephalosporins; Fluoroquinolones; Clindamycin; Ampicillin/Gentamicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-09
    Completion
    2018-12
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Stones
    Interventioncephalosporins; Fluoroquinolones; Clindamycin; Ampicillin/Gentamicin
    PhasePhase 3
    Registry statusCompleted
  • Efficacy of Amoxicillin-metronidazole Compared to Clindamycin in Patients With Periodontitis and Diabetes

    NCT03374176 · start 2014-03

    Registered record
    Registry ID
    NCT03374176
    Conditions
    Periodontitis; Periodontal Pocket; Diabetes Mellitus
    Interventions
    Amoxicillin 500 mg / Metronidazole 250 mg; Clindamycin 300 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-03
    Completion
    2017-09
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeriodontitis; Periodontal Pocket; Diabetes Mellitus
    InterventionAmoxicillin 500 mg / Metronidazole 250 mg; Clindamycin 300 mg
    PhasePhase 3
    Registry statusCompleted
  • Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris

    NCT02058628 · start 2014-02-21

    Registered record
    Registry ID
    NCT02058628
    Conditions
    Acne Vulgaris
    Interventions
    Clindamycin + BPO; Azelaic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-02-21
    Completion
    2014-09-08
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionClindamycin + BPO; Azelaic acid
    PhasePhase 4
    Registry statusCompleted